chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Shingles developed I had a a ha since the 2 Nd dose and within a few weeks of the ha the rash started I have hashimotos and  have read this can be a side effect in a small number of people; Shingles developed I had a a ha since the 2 Nd dose and within a few weeks of the ha the rash started I have hashimotos and  have read this can be a side effect in a small number of people; Shingles developed I had a a ha since the 2 Nd dose and within a few weeks of the ha the rash started I have hashimotos and  have read this can be a side effect in a small number of people; Shingles developed I had a a ha since the 2 Nd dose and within a few weeks of the ha the rash started I have hashimotos and  have read this can be a side effect in a small number of people; This is a spontaneous report from a contactable consumer (patient). A non-pregnant 46-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) via an unspecified route of administration on 21Apr2021 12:00 PM (Batch/Lot Number: Unknown) (at 46-year-old) at 2nd dose, single in arm left for COVID-19 immunization. The patient's medical history were not reported. Other medications the patient received within 2 weeks of vaccination included synthesis. The patient didn't receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient previously received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) via an unspecified route of administration on 31Mar2021 12:00 PM (Batch/Lot Number: Unknown) (at 46-year-old) at 1st dose, single in arm left for COVID-19 immunization. Prior to vaccination, the patient wasn't diagnosed with COVID-19. On 22Apr2021 12:00, shingles developed, she had a headache since the 2nd dose and within a few weeks of the headache the rash started. She had Hashimoto's and had read this can be a side effect in a small number of people. Since the vaccination, the patient hasn't been tested for COVID-19. The event resulted in emergency room visit. Therapeutic measures were taken as a result of events. The outcome of the events was resolving.  No follow-up attempts are needed. No further information is expected.
I had pain in the left arm in the first three days.  starting from day 5. I have had pain in my left armpit. In addition the armpit area has been swollen. Also I have pain in  the upper left side of my left breast
Little Stiffness Injection Site; Minor Swelling Injection Site; minor soreness injection site; This spontaneous case was reported by a consumer and describes the occurrence of MUSCULOSKELETAL STIFFNESS (Little Stiffness Injection Site), VACCINATION SITE SWELLING (Minor Swelling Injection Site) and VACCINATION SITE PAIN (minor soreness injection site) in an 88-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 17-Feb-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 18-Feb-2021, the patient experienced MUSCULOSKELETAL STIFFNESS (Little Stiffness Injection Site), VACCINATION SITE SWELLING (Minor Swelling Injection Site) and VACCINATION SITE PAIN (minor soreness injection site). At the time of the report, MUSCULOSKELETAL STIFFNESS (Little Stiffness Injection Site), VACCINATION SITE SWELLING (Minor Swelling Injection Site) and VACCINATION SITE PAIN (minor soreness injection site) had not resolved.            No concomitant medications reported by investigator o No treatment medications provided by the reporter.
herpes zoster, postherpetic neuralgia, peripheral neuropathy and balance issues; herpes zoster, postherpetic neuralgia, peripheral neuropathy and balance issues; herpes zoster, postherpetic neuralgia, peripheral neuropathy and balance issues; herpes zoster, postherpetic neuralgia, peripheral neuropathy and balance issues; Information has been received on 07-FEB-2022 from a lawyer regarding a case in litigation, concerning a patient (pt) of unknown age and gender. The pt's concurrent conditions, medical history and concomitant medications are not reported. On an unknown date, the pt was inoculated with zoster vaccine live (ZOSTAVAX) (strength, dose, route of administration, anatomical location, lot number and expiration date were not reported)  for routine health maintenance and for its intended purpose: the prevention of shingles (herpes zoster). After receiving zoster vaccine live (ZOSTAVAX) vaccine, the pt suffered herpes zoster, postherpetic neuralgia, peripheral neuropathy and balance issues. As a result of these symptoms, the pt was seen and treated by medical providers in and was still under their care. As a direct and proximate result of zoster vaccine live (ZOSTAVAX) vaccine, the pt's symptoms have resulted in physical limitations not present prior to using zoster vaccine live (ZOSTAVAX). The pt also experience mental and emotional distress due to resulting physical limitations and seriousness of the pt condition, the pt sustained severe, serious, progressive, permanent personal permanent, and incurable injuries, as well as significant conscious pain and suffering, mental anguish, emotional distress, loss of enjoyment of life, physical impairment and injury.
Patient is complaining of pain in the elbow joints after 2 weeks of getting the second dose of Pfizer.  Patient has taken ibuprofen or Tylenol which help relieves the pain but doesn't go away.  Consulted patient to f/u with pcp.  Per patient will visit pcp soon.
fever of 102, lethargy, diarrhea, lt arm red & swollen, cough;
severe headache that day. Went to ER that night for treatment.  The following Friday, November 6th, went back to ER with numbness on right side of her back that continues to come and go.  Has also had periods when she loses consciousness for short periods of time.  Has no appetite and has lost weight as a result.  Has dizziness and lightheadedness that also comes and goes. Has had follow up visit with PMD.
she got some side effects; This spontaneous case was reported by a patient and describes the occurrence of IMMUNISATION REACTION (she got some side effects) in a female patient of an unknown age who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. On an unknown date, the patient experienced IMMUNISATION REACTION (she got some side effects). At the time of the report, IMMUNISATION REACTION (she got some side effects) outcome was unknown.            No concomitant drug was reported.  Patient had no reaction on the previous vaccines she received but after getting Spikevax, she got some side effects.  No treatment drug was reported.
COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 62-year-old female patient (not pregnant) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 15Nov2022 as dose 4 (booster), single (Batch/Lot number: unknown) at the age of 61 years, in right arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown) and as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "MVP-  Endocarditis", start date: 1996 (unspecified if ongoing); "MVP-  Endocarditis", start date: 1996 (unspecified if ongoing); "Osteoporosis" (unspecified if ongoing); "Known allergies: Sulfa" (unspecified if ongoing). Concomitant medication(s) included: LYRICA, start date: 20Jun2018; METOPROLOL; SERTRALINE; NORTRIPTYLINE; EVENITY [ROMOSOZUMAB]. Past drug history included: Minocine, reaction(s): "known allergies: minocine". The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "not recovered" and all described as "COVID 19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (17Feb2023) Positive, notes: tested positive for COVID. Therapeutic measures were taken as a result of drug ineffective, covid-19 which included Paxlovid treatment from 07Feb2023 to 11Feb2023.  The information on the batch/lot number for BNT162b2, BNT162b2 omi ba.4-5 has been requested and will be submitted if and when received.
A second dose of Shingrix was administered 2 weeks after the first dose. Initial dose was 9-25-21, and then second dose was 10-11-21.
The pt developed swollen left leg from groin to knee. Also the area was warm to touch with splotchy and red. Fever of approximately 100 deg. F (ear).
Reporting system indicates adult received a pediatric dose for Pfizer first shot  Individual received full dose Pfizer (2nd shot) 12-18-21.  Sent letter and advised to repeat full dose Pfizer 21 days after 12-18-21.
Registration number (Privacy). The patient is a 13-year-4-month-old adolescent male. On December 20th, 2021 he came to the clinic for his first dose of Pfizer COVID-19 vaccine, accompanied by his mother and siblings. Shortly after receiving the vaccine, he felt anxious and complained of nausea. Prior to receiving the vaccine he felt well. EMT and medical staff on site were called to assist. The patient did not have abdominal pain, dizziness, itchiness , hives or fever.  He was offered to lay down but he was comfortable sitting instead. Vital signs remained stable during the time he was observed. BP 126/71 and 116/66; HR 74 bpm; RR 18.  Nausea did not worsen; there was no vomiting. He eventually was well within the 40 minutes he was observed. The patient was able to stand and walk without any issues. He was coherent and communicated feeling better. His mother verbalized he was better and she felt comfortable taking him home.
post nasal drip symptoms; Cough; fatigue; This is a spontaneous report from a contactable consumer (patient). A 36-year-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; Solution for injection, Lot number: EJ1685, unknown expiration), by injection to left deltoid, on 30Dec2020, at single dose for COVID 19 vaccination.  Medical history included epilepsy since 2015 and ongoing haemophilia (born with it).  There were no concomitant medications. The patient want to confirm one thing, he got the COVID 19 vaccination because he is frontline (first line worker), a paramedic, and has the lot number and all that, he got it on 30Dec2020, and last night (06Jan2021), the patient started having cough, fatigue, and stated he has been taking Tylenol. He has had no fever. The patient asked, "Is there something else that needs to be done?".  The patient has a post nasal drip symptoms (unspecified date; diagnosed a long time ago), and was prescribed albuterol for it, and has used it a couple times, but is not short of breath or nothing. He can do daily activities. The patient is planning on getting second dose, scheduled for 19Jan2021.  The patient had not recovered from the event cough, while unknown outcome for the remaining events.
Intense burning on the palms of my hands and the soles of my feet; Slight increase in temperature, around 3 degrees; Very painful neurological reaction; Soreness at injection site; Fatigue; This is a spontaneous report from a non-contactable consumer, the patient. A 74-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6204) via an unspecified route of administration in the right arm on 10Mar2021 (at the age of 74-year-old) as a single dose for COVID-19 immunisation. Medical history included Kienbock's syndrome. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient previously received codeine (MANUFACTURER UNKNOWN) from an unknown date and experienced drug allergy. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included bupropion hydrochloride (WELLBUTRIN) taken for unknown indication from an unknown start date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: L9266) via an unspecified route of administration in the right arm on 16Feb2021 (at the age of 74-year-old) as a single dose for COVID-19 immunisation. On 10Mar2021, 12 hours after vaccination, the patient was awoken by intense burning on the palms of hands and the soles of her feet, which lasted around 9 hours. The patient had slight increase in temperature, around 3 degrees, but not a real fever. The patient had very painful neurological reaction. No other intense reactions just the usual soreness at injection site and some fatigue. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. On 10Mar2021, the patient underwent body temperature test and the result was increase in temperature, around 3 degrees (units unspecified). Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event intense burning on the palms of her hands and the soles of feet, slight increase in temperature, around 3 degrees, very painful neurological reaction, soreness at injection site and fatigue was resolved on an unknown date in Mar2021.  No follow-up attempts are possible. No further information is expected.
A male patient received the second dose of BNT162B2 (Lot Number: EW0151), via an unspecified route of administration, administered in left arm on 09Apr2021 15:00  as single dose for COVID-19 immunization. Medical history included allergy with NSAID, narcotics, cloves, wheat, soy, corn, scallops, peanuts, tree nuts, environmental allergens; lupus; C2 deficiency. Concomitant medications included prednisone. The patient previously took tetracycline, minocycline, doxycycline, azithromycin, clindamycin and experienced drug allergy. The patient previously received the first dose of BNT162B2 (Lot Number: 6208) administered in left arm on 19Mar2021 15:30 as single dose for COVID-19 immunization. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination the patient was not diagnosed with COVID-19. Since the vaccination the patient has not been tested for COVID-19. Exactly two weeks after the second vaccine, the patient developed an extremely mild case of Herpes zoster virus on 23Apr2021 04:00. The adverse event resulted in Doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of the event which included 1000mg valacyclovir 3x/day. The outcome of the event was not recovered.  No follow-up attempts are needed. No further information is expected.
injection site was hot to touch; The injection site is swollen; injection site is "lumpy"/lump; shivers; he broke with hives; small red spot; hot to touch; This non-serious case was reported by a consumer via call center representative and described the occurrence of injection site warmth in a 64-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   On 03-OCT-2023, the patient received the 1st dose of Shingrix (intramuscular, left arm). On 05-OCT-2023, 2 days after receiving Shingrix, the patient experienced injection site warmth (Verbatim: injection site was hot to touch), injection site swelling (Verbatim: The injection site is swollen), injection site lump (Verbatim: injection site is "lumpy"/lump), shivering (Verbatim: shivers), hives (Verbatim: he broke with hives), localized erythema (Verbatim: small red spot) and feeling hot (Verbatim: hot to touch).  The outcome of the injection site warmth, injection site swelling, injection site lump, shivering, hives, localized erythema and feeling hot were unknown.   It was unknown if the reporter considered the injection site warmth, injection site swelling, injection site lump, shivering, hives, localized erythema and feeling hot to be related to Shingrix.     It was unknown if the company considered the injection site warmth, injection site swelling, injection site lump, shivering, hives, localized erythema and feeling hot to be related to Shingrix.   Additional Information: GSK Receipt Date: 05-OCT-2023 The reporter was the spouse of the patient. Customer reported that her husband got the 1st dose of Shingrix vaccine. The vaccine was provided at a local pharmacy. Lot and expiration date were unknown. The reporter stated that it started earlier today with a small red spot, something normal, then the last hour he broke with hives. Reporter stated the hives were in the back, chest, and both arms right down to the elbow. The injection site was lump and was swollen. The patient had shivers and the injection site was hot to touch. The reporter consented to follow up. Not all information was available. The patient provided consent to follow up with pharmacist at the pharmacy facility. Customer did not provide name of the pharmacist. The reporter said that they had 2 pharmacist in this location.
I was diagnosed with osteoporosis in May. It's probably unrelated to the vaccine, but the form asked me to report any new medical conditions, so I did, and the CDC then followed up and requested this form. If the condition is related to the vaccine, that would be really interesting.
Per the patient and daughter, red vertical line residual occurred about a week after injection. Patient agreed that it was probably not from technique of administration but a rare side effect. Not sure if there are any other causes outside of the pharmacy that may have caused this. Patient is fine and doing well at the moment, scar has healed according to patient?s daughter. Daughter of patient came in with a picture to show me (pharmacist).
Blood sugar spike  day after booster. Appointment with my endocrinologist resulting in a substantial increase in daily insulin injection (Lantus) from 12 units to 60 units. Today, 50 days after booster, is first normal reading.
Tinnitus. Very high pitched. At times, it is louder. Has been constant since onset and has never subsided. Sometimes is accompanied by headache.
Information has been received from a physician concerning a male who was vaccinated PO with his first 2.0 ml dose of ROTATEQ. Subsequently the patient developed diarrhea a "couple of days" after vaccination which lasted 2-3 weeks. Medical attention was sought at the next office visit. Subsequently, the patient recovered. There was no product quality complaint. Additional information has been requested.
Pt had swelling and pain in arm. Tennis ball sized swelling near elbow. Went to ER. Dr determined a blood vessel was punctured resulting in blood pooling in elbow. Patient treated with pain medication and antibiotic and told to follow up with PCP.
Arm from shoulder to elbo very sore for days, extremely tired, diarhea for a couple days with blood, hot and cold feeling, used heating pad
Urticaria for 3 days beginning poss 2 days p/flu vax recvd on 27OCT91;
Red, swollen from elbow to shoulder on 1/28/19 no skin breakdown, fever or chills pruritus back and arms petechaie front of calves as per patient's description.
Around 2 p.m. I started getting a headache and as the day went on it progressed into a really strong painful headache, accompanied by muscle, joint, and body aches. Also some moderate nausea.
Within 45 minutes of immunizations: generalized urticaria, SOB, exp wheezes. Tx: Epi 1:1000 SQ (0.1ml); Albuterol 2.5mg/2cc NS neb; Zyrtec 1 tsp po.
Pain at the injection site; tired; This case was reported by a consumer via interactive digital media and described the occurrence of injection site pain in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   Previously administered products included Shingrix (1st dose received on an unknown date).   In July 2022, the patient received the 2nd dose of Shingles vaccine. In July 2022, 1 day after receiving Shingles vaccine, the patient experienced injection site pain and tiredness. On an unknown date, the outcome of the injection site pain and tiredness were recovered/resolved.   It was unknown if the reporter considered the injection site pain and tiredness to be related to Shingles vaccine.     Additional Information: GSK Receipt Date: 24-Jul-2022 Reporter's comment: This case was reported by the patient via interactive digital media. The patient stated that he/she had just got the 2nd dose and was tired the next day and had some pain at the injection site.  A few coworkers have had shingles and said it was the worst pain they ever had. The patient  was fine after that and stated to get the vaccine. Follow up was not possible as no contact details were available.
Arm rash and extreme dizziness started almost immediately. After an hour the dizziness dropped some, but lasted for 2 days.  The rash extended 12 inches down from shoulder at worst point.  Starting about 1-2 days after injection I experienced a fever of over 101 F for at least 30 hours, topping out at 103.5 F (at which point I was having trouble breathing and had extreme stomach pain and considered going to ER).  To try and calm fever I took ice baths and as much Advil as possible and applied a wet compress to forehead for hours, which brought fever back to 102 range.  After and before extreme fever had slight fever for an unmeasured amount of time.  In all it took about 6 days to go through experience and recover.
History of Present Illness:  This is a 93y.o. female with medical history of hypothyroidism, dementia, H/o CVA, CKD Stage III. Patient was initially admitted to inpatient psychiatric unit on 12/22 after patient became aggressive and agitated at her current facility. During hospital stay patient tested positive for COVID 19 on 12/30. On 12/31 Patient was discharged from inpatient psych unit and transferred to general medical floor for further medical management. Patient is fully vaccinated with booster dose. During my exam at the bedside patient is pleasantly confused, wanting to continuously get up out of bed, reaching for my hands and trying to pull me towards her. Patient is able to state her name, but unable to tell me where she is or what year it is. Patient not requiring supplemental oxygen at this time.
Patient felt faint and lightheaded (syncope) and needed assistance. Called 911-felt pale and warm and had low blood pressure.
Information has been received from a licensed practical nurse concerning a 12 month old male with otitis media and no known allergies who on 9/27/01 was vaccinated SC in the right thigh with a first dose of MMR II (lot 637424/0024L). Concomitant vaccinations on 9/27/01 included a first dose SC in the left thigh of varicella virus vaccine (638728/0237L) and a first dose IM in the left thigh of Prevnar (480502). There were no other concomitant medications. On 10/3/01, the pt developed a temperature of 101-102 and became fussy. On 10/4/01, the pt's temperature was 103 and again he was very fussy. On 10/5/01, the pt was fussy; the mother administered Tylenol and laid the pt down. At 8:45 that evening th ept was cool to touch and he experienced a seizure. He was transported to the hospital (transport took approximately 15 mins). He had a temperature of 104 and was admitted to the hospital for 24 hrs observation. Unspecified lab work was drawn and "something was detected in the blood culture" which resulted in the pt being placed on antibiotics. It was noted that the "events continued until the morning of approximately 10/6/01," and the pt recovered. Additional info has been requested.
Patient reported itching and urticaria above her elbow on the same arm she received the vaccination. At 8:15 pm patient reported the urticaria was improving some and reported no further reactions.
Vertigo so severe I couldn't stand or stop vomiting. Probably more so related to surgery on 1/12 and not vaccine.